Sign up to access historical data
Similar companies
| Company | Est. Transaction Value | |
|---|---|---|
 |
PfizerPFE |
-$87,000 |
 |
AstrazenecaAZN |
$32,000 |
 |
Johnson & JohnsonJNJ |
-$230,000 |
 |
ModernaMRNA |
$24,000 |
 |
AbbVieABBV |
$88,000 |
Trades by US Politicians
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| David Taylor | Jan 16, 2026 | Sell | $1K - $15K |
| Julie Johnson | Dec 18, 2025 | Sell | $1K - $15K |
| David Taylor | Dec 10, 2025 | Sell | $1K - $15K |
| Gilbert Cisneros | Nov 18, 2025 | Buy | $1K - $15K |
| Julie Johnson | Nov 13, 2025 | Sell | $1K - $15K |
| Val Hoyle | Sep 23, 2025 | Sell | $1K - $15K |
| Julie Johnson | Aug 14, 2025 | Sell | $1K - $15K |
| David Taylor | Aug 14, 2025 | Buy | $15K - $50K |
| Lisa McClain | Jul 10, 2025 | Buy | $1K - $15K |
| Ro Khanna | Jul 2, 2025 | Buy | $1K - $15K |
| Ro Khanna | Jun 6, 2025 | Buy | $1K - $15K |
| Jonathan Jackson | Jun 3, 2025 | Sell | $15K - $50K |
| Gilbert Cisneros | May 30, 2025 | Sell | $1K - $15K |
| Jonathan Jackson | May 21, 2025 | Sell | $1K - $15K |
| Marjorie Taylor Greene | May 14, 2025 | Buy | $1K - $15K |
| Josh Gottheimer | May 13, 2025 | Sell | $1K - $15K |
| Marjorie Taylor Greene | May 5, 2025 | Buy | $1K - $15K |
| Josh Gottheimer | May 1, 2025 | Buy | $1K - $15K |
| Jonathan Jackson | Apr 23, 2025 | Buy | $1K - $15K |
| Jonathan Jackson | Apr 21, 2025 | Buy | $15K - $50K |
| Bruce Westerman | Apr 21, 2025 | Sell | $1K - $15K |
| Dan Newhouse | Apr 11, 2025 | Sell | $1K - $15K |
| Rob Bresnahan | Apr 8, 2025 | Sell | $1K - $15K |
| Julie Johnson | Apr 7, 2025 | Sell | $1K - $15K |
| Josh Gottheimer | Mar 10, 2025 | Sell | $1K - $15K |
| Bruce Westerman | Mar 3, 2025 | Buy | $1K - $15K |
| Josh Gottheimer | Feb 19, 2025 | Sell | $1K - $15K |
| Marjorie Taylor Greene | Jan 21, 2025 | Buy | $1K - $15K |
| Josh Gottheimer | Jan 8, 2025 | Sell | $1K - $15K |
| Marjorie Taylor Greene | Dec 24, 2024 | Buy | $1K - $15K |
| Josh Gottheimer | Dec 18, 2024 | Sell | $1K - $15K |
| Josh Gottheimer | Dec 16, 2024 | Sell | $1K - $15K |
| Josh Gottheimer | Dec 13, 2024 | Sell | $1K - $15K |
| Josh Gottheimer | Dec 12, 2024 | Sell | $1K - $15K |
| Josh Gottheimer | Dec 11, 2024 | Sell | $1K - $15K |
| Lisa McClain | Dec 11, 2024 | Buy | $1K - $15K |
| Josh Gottheimer | Dec 10, 2024 | Sell | $1K - $15K |
| Josh Gottheimer | Dec 9, 2024 | Sell | $1K - $15K |
| Josh Gottheimer | Nov 19, 2024 | Sell | $1K - $15K |
| Josh Gottheimer | Nov 14, 2024 | Sell | $1K - $15K |
| Greg Landsman | Nov 8, 2024 | Sell | $15K - $50K |
| Ro Khanna | Nov 1, 2024 | Sell | $15K - $50K |
| Valerie Hoyle | Oct 29, 2024 | Buy | $1K - $15K |
| Josh Gottheimer | Oct 16, 2024 | Sell | $1K - $15K |
| Ro Khanna | Jun 7, 2024 | Sell | $1K - $15K |
| Rohit Khanna Democrat | Apr 23, 2024 | Sell | $1K - $15K |
| Daniel Newhouse Republican | Apr 10, 2024 | Sell | $1K - $15K |
| Rohit Khanna Democrat | Apr 5, 2024 | Sell | $15K - $50K |
| Thomas Tuberville Republican | Apr 3, 2024 | Sell | $15K - $50K |
| Rohit Khanna Democrat | Mar 1, 2024 | Sell | $1K - $15K |
| Rohit Khanna Democrat | Feb 13, 2024 | Sell | $1K - $15K |
FAQ - Congress Trading
David Taylor sold Eli Lilly and Company shares most recently on January 16, 2026.
Jonathan Jackson has bought the most LLY stock in the last 2 years, with an estimated value of $41,000.
Josh Gottheimer has sold the most LLY stock in the last 2 years, with an estimated value of $110,000.
The net value of trades by US politicians for Eli Lilly and Company in the last 2 years is negative, amounting to -$240,000. This suggests that US politicians do not believe in the success of the company for various reasons.
Over the last 2 years, insider transactions for Eli Lilly and Company have largely consisted of selling shares, which could suggest various personal or financial motivations among insiders. The higher number of sales might require investors to investigate further, considering politicians might have insights or reasons not immediately apparent to the public.
Monitoring US politicians' stock trades is valuable because they may have inside information about upcoming policies that could affect stock values, providing investors with valuable clues for making informed decisions.
